Determinants of red blood cell alloantibody detection duration: analysis of multiply alloimmunized patients supports peritransfusion factors

Transfusion

Volumn 57, Issue 8, 2017, Pages 1930-1937

  Noiret, Lorette ^a   Slater, Amy ^a,b   Higgins, John M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY;

ADULT; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; TIME; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; ERYTHROCYTE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR; TRANSFUSION REACTION; YOUNG ADULT;

ADULT; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSFUSION REACTION; YOUNG ADULT;

EID: 85021353350     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14157     Document Type: Article

References (18)

1. Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003;43:945-52.
2. Zalpuri S, Middelburg RA, Schonewille H, et al. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion 2014;54:278-84.
3. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008;112:2546-53.
4. Natukunda B, Brand A, Schonewille H. Red blood cell alloimmunization from an African perspective. Curr Opin Hematol 2010;17:565-70.
5. Alves VM, Martins PR, Soares S, et al. Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter 2012;34:206-11.
6. Schonewille H, Van De Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630-5.
7. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008;6:225-34.
8. Ramsey G, Larson P. Loss of red cell alloantibodies over time. Transfusion 1988;28:162-5.
9. Ramsey G, Smietana SJ. Long-term follow-up testing of red cell alloantibodies. Transfusion 1994;34:122-4.
10. Schonewille H, Haak HL, Van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127-31.
11. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505-12.
12. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-73.
13. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013;89:434-44.
14. Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion 2016;56:2662-7.
15. Hendrickson JE, Chadwick TE, Roback JD, et al. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood 2007;110:2736-43.
16. Smith NH, Hod EA, Spitalnik SL, et al. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 2012;119:1566-9.
17. Yazer MH, Triulzi DJ, Shaz B, et al. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 2009;49:1070-5.
18. Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion 2009;49:2709-18.